## Pinelopi Samara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11162266/publications.pdf

Version: 2024-02-01

23 papers 535 citations

758635 12 h-index 713013 21 g-index

23 all docs 23 docs citations

23 times ranked

1006 citing authors

#	Article	IF	Citations
1	miRNA polymorphisms and risk of premature coronary artery disease. Hellenic Journal of Cardiology, 2021, 62, 278-284.	0.4	15
2	Prothymosin $\hat{l}_{\pm}$ and Its C-Terminal Immunoreactive Decapeptide Show no Evidence of Acute Toxicity: A Preliminary in Silico, in Vitro and in Vivo Investigation. Current Medicinal Chemistry, 2021, 28, .	1.2	1
3	Study on the admission levels of circulating cell-free DNA in patients with acute myocardial infarction using different quantification methods. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 348-350.	0.6	3
4	Antiproliferative Activity of (-)-Rabdosiin Isolated from Ocimum sanctum L Medicines (Basel,) Tj ETQq0 0 0 rgB	「/Oyerloch	₹ 10 Jf 50 622
5	Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. Cancers, 2019, 11, 1764.	1.7	10
6	Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. Redox Biology, 2018, 16, 169-178.	3.9	37
7	2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15–17, 2016, Athens, Greece. Cancer Immunology, Immunotherapy, 2018, 67, 153-159.	2.0	O
8	Expression of miR-208b and miR-499 in Greek Patients with Acute Myocardial Infarction. In Vivo, 2018, 32, 313-318.	0.6	24
9	New semi-synthetic analogs of oleuropein show improved anticancer activity inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2017, 137, 11-29.	2.6	27
10	A fragment of the alarmin prothymosin $\hat{l}\pm$ as a novel biomarker in murine models of bacteria-induced sepsis. Oncotarget, 2017, 8, 48635-48649.	0.8	6
11	Prothymosin Alpha: An Alarmin and More Current Medicinal Chemistry, 2017, 24, 1747-1760.	1.2	25
12	Harnessing the immune system to improve cancer therapy. Annals of Translational Medicine, 2016, 4, 261-261.	0.7	225
13	A flow cytometric approach for studying alterations in the cytoplasmic concentration of calcium ions in immune cells following stimulation with thymic peptides. Cellular Immunology, 2016, 302, 32-40.	1.4	6
14	A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer. Anticancer Research, 2016, 36, 3373-82.	0.5	3
15	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2621-2623.	1.0	2
16	Specific in vitro binding of a new 99mTc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils. International Journal of Pharmaceutics, 2015, 486, 1-12.	2.6	18
17	Activation of the human natural killer cells NK-92 with a lymphocyte-derived cytokine-rich supernatant Journal of Clinical Oncology, 2014, 32, 3108-3108.	0.8	1
18	Immune responses induced by the TLR-4 agonist-based adjuvant prothymosin alpha Journal of Clinical Oncology, 2014, 32, 11131-11131.	0.8	0

#	Article	IF	CITATIONS
19	Prothymosin α and a prothymosin α-derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes. BMC Immunology, 2013, 14, 43.	0.9	22
20	The C-terminal decapeptide of prothymosin $\hat{l}_{\pm}$ is responsible for its stimulatory effect on the functions of human neutrophils in vitro. International Immunopharmacology, 2013, 15, 50-57.	1.7	16
21	Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin α(100–109) in sera of mice infected with bacteria. Journal of Immunological Methods, 2013, 395, 54-62.	0.6	10
22	Polar Constituents of <i>Marrubium thessalum</i> Boiss. & Diss. & Diss	2.8	30
23	Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy. Cancer Immunology, Immunotherapy, 2012, 61, 599-614.	2.0	39